Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch, Axxam Collaborate on Cell-based Assays

NEW YORK (GenomeWeb News) – Cellectis Bioresearch today announced a collaboration with Axxam to offer integrated discovery services based on genomic engineering technologies.

According to Cellectis, a genome engineering firm, the collaboration will offer a one-stop shop approach to generating cell-based assays to the life science industry. Cellectis will use its genome engineering methods to modify genes of interest, and then Axxam will apply its expertise and technologies for cell line generation to develop functional cellular assays.

Cellectis said that with current genome engineering technologies almost any gene at any position and in any cell type can be addressed for applications from knock-in insertions and knock-out deletions to reporter cell-line generations, and others.

Financial and other terms of the agreement were not disclosed.

“For the first time, any modification at the genomic level can be introduced into a cellular assay, thereby increasing significantly the repertoire for generating the most relevant assay format for a given target,” Axxam CEO Stefan Lohmer said in a statement. The firm provides discovery services including assay development for high-throughput screening.